Myelofibrosis is an inflammation-driven systemic disease in which cytokines, fibrosis and clonal evolution are inextricably linked. New data show that the control of inflammation has a decisive influence on the course of the disease. Modern therapies that simultaneously modulate JAK signaling pathways, hepcidin regulation and inflammatory networks mark a real paradigm shift.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?
New study on atrial fibrillation in high-risk patients
- Peristomal skin health
Focus on preventive care options
- Planning a Family, Pregnancy, and Breastfeeding
Update on Anti-Rheumatic Medications
- Mental Health with GLP-1 RAs
Benefits of Semaglutide and Liraglutide
- Bronchiolitis obliterans
Out of shape even without popcorn
- Case study